Cargando…
Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function
Omega-3 fatty acid prescription drugs, Vascepa (≥96% eicosapentaenoic acid [EPA] ethyl ester) and Lovaza (46.5% EPA and 37.5% docosahexaenoic acid ethyl ester) are known therapeutic regimens to treat hypertriglyceridemia. However, their impact on glucose homeostasis, progression to type 2 diabetes,...
Autores principales: | Al Rijjal, Dana, Liu, Ying, Lai, Mi, Song, Youchen, Danaei, Zahra, Wu, Anne, Mohan, Haneesha, Wei, Li, Schopfer, Francisco J., Dai, Feihan F., Wheeler, Michael B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379293/ https://www.ncbi.nlm.nih.gov/pubmed/34458694 http://dx.doi.org/10.1016/j.isci.2021.102909 |
Ejemplares similares
-
Icosapent Ethyl (Vascepa®) for the Treatment of Acute, Severe Pancreatitis
por: Berger, Amnon A, et al.
Publicado: (2020) -
Underlying dyslipidemia postpartum in women with a recent GDM pregnancy who develop type 2 diabetes
por: Lai, Mi, et al.
Publicado: (2020) -
A protocol for studying glucose homeostasis and islet function in mice
por: Al Rijjal, Dana, et al.
Publicado: (2022) -
Inhibition of Id1 Augments Insulin Secretion and Protects Against High-Fat Diet–Induced Glucose Intolerance
por: Åkerfeldt, Mia C., et al.
Publicado: (2011) -
Antiretroviral therapy potentiates high-fat diet induced obesity and glucose intolerance
por: Pepin, Mark E., et al.
Publicado: (2018)